PLCG2 and B-cell chronic lymphocytic leukemia: On-target BTK mutations (e.g. A428D, V416L, T474I, M437R, L528W) and PLCγ2 mutations allow CLL cells to escape the BTK inhibitory effects in CLL patients treated with the noncovalent inhibitor pirtobrutinib (156).